An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Tykerb® Administered in Korean Patients According to the Prescribing Information
Non-interventional, open-label, single group, multicentric post-marketing surveillance to
monitor the safety and effectiveness of Tykerb® administered in Korean patients according to
the prescribing information
Tykerb® will be administered with capecitabine for ErbB2 overexpressing cancer treatment as
described the prescribing information of Tykerb® or by physician's decision. Moreover, the
data from the patients with Tykerb® monotherapy or with other combination than capecitabine
will be also included if physicians in charge decide to treat with Tykerb®.
Observational
Time Perspective: Prospective
Occurrence of adverse events after Tykerb® administration
12 months
Yes
GSK Clinical Trials
Study Director
GlaxoSmithKline
Korea: Korea Food & Drug Administration
112477
NCT00975988
January 2010
October 2013
Name | Location |
---|